alexa Treatment Of Grade IV Diffuse Lamellar Keratitis (DLK) With Oral Doxycycline And Topical 10% Sodium Citrate
ISSN: 2167-1079

Primary Healthcare: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd Annual Congress & Medicare Expo on Primary Healthcare, Clinical & Medical Case Reports
April 17-19, 2017 Dubai, UAE

Jarade Elias, Slim E, Antoun J and Abou Khzam R
The Dubai Mall Medical Center, UAE
ScientificTracks Abstracts: Primary Health Care
DOI: 10.4172/2167-1079-C1-005
Abstract
Purpose: The purpose of the study is to report a new treatment strategy of grade IV diffuse lamellar keratitis (DLK) based on topical 10% sodium citrate and oral Doxycycline. Methods: Six eyes of 3 patients with stage IV DLK after LASIK, were treated with the same treatment protocol of 10% topical sodium citrate 6 times a day for 4 weeks and 100 mg oral Doxycycline twice daily for 2 weeks then once daily for three months, along with topical steroid drops for one week then tapered gradually over one month. Assessment of response to treatment was done in terms of visual acuity, anatomical and keratometric recovery for the period of follow up ranging from 1 to 8 years. Results: Follow-up visits showed improvement in all eyes, starting at 2 weeks, with an improvement in UCVA, a decrease in hyperopia and in the central corneal infiltrates. Progressive improvement was documented during the follow up. At 1 year, the outcome regarding UCVA, hyperopia and clinical findings was excellent reaching 20/30 to 20/20 OU, with residual hyperopia of +0.25 D to +1.25 D and a complete resolution of the central infiltrates. Conclusion: This is the first report of successful treatment of stage IV DLK. Topical sodium citrate 10% and oral Doxycycline seem to target the main pathophysiology of the disease through their mechanism of anti-collagenolytic activities. This new treatment strategy might be considered in the treatment of corneal inflammatory conditions characterized by increased collagenolytic activities after LASIK. Precis: In stage IV DLK, stromal collagen is digested by collagenolytic enzymes. We report a new treatment strategy of grade IV DLK, based on topical sodium citrate and oral Doxycycline with good anatomical and functional outcomes.
Biography

Jarade Elias is a graduate of Harvard Medical School with 2 certificates of fellowship in Cornea and Refractive Surgery from the Eye Center and Eye Foundation for Research, and The Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, USA and Head of the Cornea and Refractive Surgery Department at Beirut Eye Specialist Hospital. He is heavily involved in the practice and research of cornea, cataract, refractive surgery and cornea transplant and has to his record more than 50 peer reviewed scientific papers, chapters and reviews, also Presenter and Invited Faculty in the field of cornea and refractive surgery at international meetings. He has been serving as an Editorial Board Member of the Journal of Refractive Surgery, Expert Board Member of the International Journal of Ophthalmology, Guest Editor of the Journal of Ophthalmology (current concept in corneal collagen crosslinking), Lead Guest Editor for a special issue of Bio Med Journal, International Advisory Board for the Saudi Journal of Ophthalmology and a County Liaison and Regional Representative of “Tear film and Ocular Surface Society (TFOS)”. His research interest includes refractive surgery, corneal transplant, ocular surface disease, keratoconus, and retinal degenerative disease. He is leading a registered clinical trial for the treatment of retinitis pigmentosa, new treatment modalities of keratoectasia and new glaucoma filtering procedure.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords